Abbott's spin-off AbbVie to join S&P 100 & 500

Thu Dec 20, 2012 6:43pm EST

Dec 20 (Reuters) - AbbVie Inc, the pharmaceutical company being spun off by Abbott Laboratories, is set to join the Standard and Poor's 100 and 500 indices, S&P Dow Jones Indices said.

AbbVie will replace Dell Inc in the S&P 100 and Federated Investors Inc in the S&P 500.

Abbott Labs will remain in both indices.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.